ALKBH8 and Zika virus infectious disease: ShRNAs targeting ALKBH8 and CTU1 both led to a significant reduction in SARS-CoV-2 and ZIKV infection levels compared to cells treated with the control shRNA (IRV1) (Figure 5C,D).